✦ LIBER ✦

Clinical applications of rIL-2 and LAK cells in patients with brain tumors

✍ Scribed by K. Shimizu; K. Tamura; Y. Okamoto; Y. Miyao; M. Yamada; Y. Matsui; K. Park; H. Mogami

Publisher: Elsevier Science
Year: 1988
Tongue: English
Weight: 87 KB
Volume: 10
Category: Article
ISSN: 0192-0561
DOI: 10.1016/0192-0561(88)90415-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Impact of fMRI-guided advanced DTI fiber

Impact of fMRI-guided advanced DTI fiber tracking techniques on their clinical applications in patients with brain tumors

✍ Raimund Kleiser; Philipp Staempfli; Anton Valavanis; Peter Boesiger; Spyros Koll 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 465 KB

Alteration of serum and tumoral neural c

Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors

✍ Laura Todaro; Silvia Christiansen; Mirta Varela; Paola Campodónico; M. Guadalupe 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 406 KB

Serum concentrations of soluble interleu

Serum concentrations of soluble interleukin-2 receptor in patients with malignant brain tumors

✍ Seiichi Yoshida; Ken Morii 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views

Clinical application of event related po

Clinical application of event related potentials in patients with brain tumours and traumatic head injuries

✍ H. M. Olbrich; H. E. Nau; D. Zerbin; L. Lanczos; E. Lodemann; M. P. Engelmeier; 📂 Article 📅 1986 🏛 Springer Vienna 🌐 English ⚖ 615 KB

Effect of shenmai Injection on SIL-2R NK

Effect of shenmai Injection on SIL-2R NK and LAK cells of patients with advanced carcinoma

✍ Pei-fang Feng; Lu-ming Liu; Yu-ying Shen 📂 Article 📅 1995 🏛 Chinese Association of Traditional and Western Med 🌐 English ⚖ 215 KB

Serum tumor markers and patient allocati

Serum tumor markers and patient allocation to good-risk and poor-risk clinical trials in patients with germ cell tumors

✍ George J. Bosl; Nancy L. Geller; Dean Bajorin 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 552 KB

The allocation of patients with advanced germ cell tumors (GCT) to different treatment programs based on clinical characteristics is standard in the design of clinical trials today. Studies have shown that substantial differences exist between entry criteria and that these differences could influenc